Media stories about Alnylam Pharmaceuticals (NASDAQ:ALNY) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 40 out of 100, indicating that recent press coverage is unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Are Discerning Investors Interested in China Lodging Group, Limited (NASDAQ:HTHT) or Alnylam Pharmaceuticals, Inc … – FLBC News (flbcnews.com)
- Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss (finance.yahoo.com)
- Alnylam Pharmaceuticals’ (NASDAQ:ALNY) “Buy” Rating Reiterated at Chardan Capital (americanbankingnews.com)
- Alnylam review turns up no clear answers on revusiran deaths – BioPharma Dive (biopharmadive.com)
- Alnylam Pharmaceuticals (ALNY) Q2 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 2.983% during mid-day trading on Friday, hitting $78.205. 700,413 shares of the company were exchanged. The company’s 50-day moving average price is $81.11 and its 200-day moving average price is $61.63. The firm’s market capitalization is $6.89 billion. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $86.92.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.12. The company had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 48.01% and a negative net margin of 670.81%. The business’s quarterly revenue was up 82.9% on a year-over-year basis. During the same quarter last year, the business posted ($1.05) EPS. Equities research analysts predict that Alnylam Pharmaceuticals will post ($5.23) earnings per share for the current fiscal year.
A number of equities research analysts recently issued reports on ALNY shares. BMO Capital Markets started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, April 17th. They issued an “outperform” rating and a $73.00 price objective for the company. Chardan Capital set a $95.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, May 5th. Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $39.00 to $42.00 and gave the company an “equal weight” rating in a report on Monday, May 8th. Credit Suisse Group restated a “hold” rating and set a $50.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 9th. Finally, Piper Jaffray Companies set a $118.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $81.74.
ILLEGAL ACTIVITY WARNING: This article was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/11/alnylam-pharmaceuticals-alny-receives-media-impact-rating-of-0-16-updated-updated-updated.html.
In other news, VP Michael Mason sold 9,375 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total value of $656,250.00. Following the completion of the transaction, the vice president now directly owns 5,625 shares in the company, valued at $393,750. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Akshay Vaishnaw sold 11,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the sale, the executive vice president now owns 21,297 shares of the company’s stock, valued at $1,597,275. The disclosure for this sale can be found here. Insiders sold 64,125 shares of company stock valued at $4,325,000 in the last quarter. Corporate insiders own 4.30% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
What are top analysts saying about Alnylam Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alnylam Pharmaceuticals Inc. and related companies.